Radiation targeting for advanced esophageal cancer with immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial studies how to best target radiation for people with advanced esophageal cancer who are also getting immunotherapy. It aims to improve treatment planning to help patients live longer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of esophageal cancer called squamous cell carcinoma.
- Your cancer is locally advanced but has not spread to distant organs.
- You are scheduled to receive radiation therapy along with immunotherapy or before surgery.
- You are physically able to care for yourself (ECOG status 0-2).
- Your doctor expects you to live at least 6 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
This trial tests different doses of radiation therapy combined with the immunotherapy drug sintilimab for people with locally advanced esophageal squamous cell carcinoma. The goal is to find the best radiation dose to improve treatment outcomes.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
This trial tests a new immunotherapy drug called toripalimab, given before, during, and after standard radiation and chemotherapy for esophageal cancer that hasn't spread. The goal is to see if adding this drug can improve outcomes for patients.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.